X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association and the proud father of his poodle-beagle mix Molly.

Recent Posts

ICYMI: New study shows medicines advance life expectancy for HIV patients

By Andrew Powaleny  |    May 15, 2017
In the three decades since the HIV/AIDS crisis first struck the United States, incredible strides have been made in understanding and treating this disease.   Read More

Clinical Trials Awareness Week: Celebrating the impact of clinical research

By Andrew Powaleny  |    May 1, 2017
Today starts off the beginning of Clinical Trials Awareness Week, which shines a spotlight on how the clinical trials process helps deliver safe, effective medicines to patients.   Read More

ICYMI: The New Era of Medicine initiative spotlights genomics in NYC

By Andrew Powaleny  |    April 28, 2017
As the understanding of each person’s unique DNA makeup continues to grow (better known as genomics), personalized medicine is rapidly reaching new heights.   Read More

A new era in genomics

By Andrew Powaleny  |    April 26, 2017
Personalized medicine has taken on a new meaning with the mapping of the human genome.   Read More

ICYMI: Report highlights overall decrease in cancer death rates

By Andrew Powaleny  |    April 3, 2017
In case you missed it, cancer death rates are continuing to decrease for men, women and children in the United States thanks in part to biopharmaceutical innovation, according to the Annual Report...   Read More

ICYMI: New era of medicine initiative kicks off in Boston

By Andrew Powaleny  |    February 22, 2017
It’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care...   Read More

Watch: Biomarkers in drug development with Dr. Bernie Zeiher

By Andrew Powaleny  |    February 14, 2017
Biomarkers are powerful tools which are used by medical professionals in many ways, including in the diagnosis of disease, monitoring how a disease is progressing and, if a treatment is given, how...   Read More

The 20-year journey yielding a new weapon against cancer

By Andrew Powaleny  |    January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...   Read More

3 things to know about 2016 drug approvals

By Andrew Powaleny  |    January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...   Read More

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates